Fairvalue-Calculator Fairvalue-Calculator
EN DE

Fresenius SE (FSNUY) Fair Value & Analysis

Healthcare · US · Market cap $25.4B

Price$11.47
Fair Value$8.55
Upside-25.5%
Quality93/100
Evidence: High Range $7.44 – $12.95

Analysis

Fresenius SE (FSNUY) currently trades at $11.47, while our model-based Fair Value estimate is $8.55 — implying the stock looks roughly 25.5% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-nativ…

Open the full interactive analysis →

Similar stocks

HCA Healthcare, Inc (H1CA34) +19% 5225 (5225) -39% IHHHF (IHHHF) -57% Tenet Healthcare Corporation (THC) +86% Rede D'Or São Luiz S.A (RDOR3) +37% Fresenius Medical Care AG (FMS) +96%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.